Clinical and Cognitive Sciences Research Group, Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Salford Royal Hospital, Salford.
Neuropathol Appl Neurobiol. 2014 Dec;40(7):844-54. doi: 10.1111/nan.12155.
Frontotemporal lobar degeneration (FTLD) is classified mainly into FTLD-tau and FTLD-TDP according to the protein present within inclusion bodies. While such a classification implies only a single type of protein should be present, recent studies have demonstrated dual tau and TDP-43 proteinopathy can occur, particularly in inherited FTLD.
We therefore investigated 33 patients with FTLD-tau (including 9 with MAPT mutation) for TDP-43 pathological changes, and 45 patients with FTLD-TDP (including 12 with hexanucleotide expansion in C9ORF72 and 12 with GRN mutation), and 23 patients with motor neurone disease (3 with hexanucleotide expansion in C9ORF72), for tauopathy.
TDP-43 pathological changes, of the kind seen in many elderly individuals with Alzheimer's disease, were seen in only two FTLD-tau cases--a 70-year-old male with exon 10 + 13 mutation in MAPT, and a 73-year-old female with corticobasal degeneration. Such changes were considered to be secondary and probably reflective of advanced age. Conversely, there was generally only scant tau pathology, usually only within hippocampus and/or entorhinal cortex, in most patients with FTLD-TDP or MND. The extent of tau pathology in FTLD-TDP and MND, as with amyloid β protein, may relate to increased age and possession of Apolipoprotein ε4 allele.
We find no predilection or predisposition towards an accompanying TDP-43 pathology in patients with FTLD-tau, irrespective of presence or absence of MAPT mutation, or that genetic changes associated with FTLD-TDP predispose towards excessive tauopathy. Where the two processes coexist, this is limited and probably causatively independent of each other.
额颞叶变性(FTLD)主要根据包涵体内存在的蛋白分为 FTLD-tau 和 FTLD-TDP。虽然这种分类仅意味着应该存在一种类型的蛋白,但最近的研究表明,双 tau 和 TDP-43 蛋白病可能会发生,特别是在遗传性 FTLD 中。
因此,我们调查了 33 例 FTLD-tau 患者(包括 9 例 MAPT 突变)的 TDP-43 病理改变,45 例 FTLD-TDP 患者(包括 12 例 C9ORF72 六核苷酸扩展和 12 例 GRN 突变),和 23 例运动神经元病患者(3 例 C9ORF72 六核苷酸扩展)的 tau 病。
仅在 2 例 FTLD-tau 病例中观察到与许多老年阿尔茨海默病患者所见相似的 TDP-43 病理改变——一例 70 岁男性 MAPT 外显子 10+13 突变,另一例 73 岁女性皮质基底节变性。这种改变被认为是继发性的,可能反映了高龄。相反,大多数 FTLD-TDP 或 MND 患者的 tau 病理通常仅为海马和/或内嗅皮质内存在少量 tau 病理。FTLD-TDP 和 MND 中的 tau 病理程度,如淀粉样 β 蛋白,可能与年龄增加和载脂蛋白 E4 等位基因有关。
我们发现 FTLD-tau 患者中不存在伴随 TDP-43 病理的倾向或易感性,无论是否存在 MAPT 突变,或与 FTLD-TDP 相关的遗传变化是否导致 tau 病过度发生。当这两个过程并存时,这种情况是有限的,并且可能彼此独立。